Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Annual Report
BriaCell Therapeutics Corp. has reached its limit for free report views.
Work for BriaCell Therapeutics Corp.?
Claim Your Profile
BriaCell Therapeutics Corp.
About BriaCell Therapeutics Corp.
1-10 Employees
Based in Berkeley, California
BriaCell (TSXV: BCT) (OTCQB: BCTXF) is a clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT™, in advanced breast cancer along with the co-development of BriaDX™, its companion diagnostic. Additionally, there is an FDA approved combination study of Bria-IMT™ with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT™. Moreover, BriaCell is developing Bria-OTS™, the first “off the shelf” personalized treatment for advanced stage Breast Cancer. BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases.
- Ticker:
- BCTX
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Biotechnology (See More Biotechnology Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
